NAD+ & NMN — Benefits Deep Dive

Benefits — scientific infographic poster

NAD+ sits at the intersection of four distinct areas of biology: (1) it is the master substrate for the sirtuin family of longevity-regulating enzymes, (2) it is the electron carrier without which mitochondrial ATP production collapses, (3) it is the cofactor that PARP enzymes burn through to repair DNA damage, and (4) its levels are lower with age in several tissues — in mice a median drop of about 30% across tissues, in people reported declines in skin, brain and muscle, while human blood data are mixed. Each benefit page below explores one of these territories and the human trials behind it, including the David Sinclair sirtuin program, the brain-NAD+ trials, the bioenergetics literature, and the structural and regulatory differences between the four available B3 precursors (niacin, niacinamide, NR, NMN).

Deep-Dive Articles

⏳

Longevity & Sirtuins

The David Sinclair lab program at Harvard Medical School, the sirtuin family (SIRT1–SIRT7) as NAD+-dependent deacetylases, telomere maintenance via SIRT6, the SIRT3 mitochondrial protection axis, autophagy regulation, FOXO transcription factor activation, the "NAD+ decline = aging" hypothesis, the mouse lifespan results (mixed), and the Brenner vs Sinclair NMN-vs-NR scientific debate.

Read the deep dive →
🧠

Cognition & Brain Health

NAD+ in the central nervous system, brain SIRT1 activation, the blood-brain barrier question, the mouse studies, the Parkinson's pilot data, neuroinflammation, and an account of the small published NR and NMN trials in people, which have not found a cognitive effect so far.

Read the deep dive →
⚡

Energy & Mitochondria

NAD+ as universal electron carrier (Complex I substrate), the NAD+/NADH ratio as bioenergetic indicator, mitochondrial unfolded protein response (UPRmt) activation, AMPK + sirtuin cross-talk, ATP production, what the exercise trials found, the chronic-fatigue and long-COVID rationale, and what is known about IV NAD+ infusions.

Read the deep dive →
⚖️

NAD Precursors Compared

Niacin (NA) vs niacinamide (NAM) vs nicotinamide riboside (NR) vs nicotinamide mononucleotide (NMN): absorption, the FDA's 2022 exclusion of NMN and its September 2025 reversal, why more human trials have used NR, Sinclair's NMN advocacy, niacin's vasodilator flush, and the Brenner methylation-cofactor critique.

Read the deep dive →

Back to Table of Contents

Table of Contents

  1. Deep-Dive Articles
  2. Why NAD+ Repletion Produces Effects Across So Many Systems
  3. Research Papers: Longevity & Sirtuins
  4. Research Papers: Cognition & Brain
  5. Research Papers: Energy & Mitochondria
  6. Research Papers: NAD Precursors & Pharmacokinetics
  7. Research Papers: Cross-Cutting (Safety, Regulation, Mechanism)
  8. External Authoritative Resources
  9. Connections
  10. Featured Videos

Why NAD+ Repletion Produces Effects Across So Many Systems

Most supplements act on one or two enzymes or one or two tissues. NAD+ is unusual because it is consumed as a substrate by at least three large enzyme families (sirtuins, PARPs, CD38) and is required as an electron carrier in every mitochondrion. Its levels are lower with age in several tissues: in aged mice, isotope tracing found a median decrease of about 30% across tissues (McReynolds and colleagues, 2021); in people, declines have been reported in skin, brain and skeletal muscle, while blood results are mixed, and a 2026 seven-cohort study found whole-blood NAD+ stable with age (Trętowicz and colleagues, 2026). A frequently quoted figure of a 50% fall by middle age was not found as a measured human result. Raising NAD+ therefore touches a wide range of biology in cells and animals; which of these effects carry over to people is what the human trials test.

  1. Sirtuin substrate — SIRT1, SIRT3, and SIRT6 are the best-characterized; each uses NAD+ to remove acetyl groups from target proteins. Researchers propose that restoring NAD+ supports sirtuin activity, with effects on autophagy, DNA repair, mitochondrial biogenesis, and inflammation — a hypothesis based mainly on mouse and cell studies. Explored in Longevity & Sirtuins.
  2. Mitochondrial electron carrier — NADH donates electrons to Complex I of the electron transport chain. When NAD+ is scarce in cell and animal experiments, less ATP is made and more reactive oxygen species leak from the chain. This is the basis for the fatigue, exercise-capacity, and bioenergetic research; in older men, NR raised the muscle NAD+ metabolome but did not change mitochondrial bioenergetics (Elhassan and colleagues, 2019).
  3. PARP cofactor for DNA repair — PARP1 and PARP2 use NAD+ to flag DNA single-strand and double-strand breaks for repair. Under severe DNA damage in cells, PARP activation can deplete NAD+ sharply and quickly. In human skin samples, PARP activity rose with age in males and was inversely related to tissue NAD+ (Massudi and colleagues, 2012).
  4. CD38 substrate — the consumer that rises with inflammaging — CD38 is an NADase whose expression rises with age on inflammatory immune cells in mice. In mouse experiments CD38 was required for the age-related NAD+ decline (Camacho-Pereira and colleagues, 2016); whether blocking CD38 helps in people has not been shown.
  5. Brain access — how NMN enters cells is disputed: a 2019 mouse study reported that Slc12a8 is an NMN transporter in the small intestine, and other researchers argued the evidence did not show this; a 2025 mouse study found most oral NMN and NR was converted by gut bacteria to nicotinic acid before feeding NAD+ synthesis. The cognition page covers what is known about brain NAD+.

The four B3 precursors (niacin, niacinamide, NR, NMN) differ in absorption, metabolism, side effects and the size of their clinical evidence. The precursors comparison page walks through the Brenner critique, the Sinclair advocacy, and the FDA's 29 September 2025 reversal that ended NMN's 2022 exclusion from the US dietary-supplement definition.

Back to Table of Contents

Research Papers: Longevity & Sirtuins

  1. Imai & Guarente — NAD+ and sirtuins in aging and disease (Trends Cell Biol 2014) — PubMed PMID: 24786309
  2. Bonkowski & Sinclair — Slowing ageing by design: NAD+ and STACs (Nat Rev Mol Cell Biol 2016) — PubMed PMID: 27552971
  3. Mills et al. — Long-term NMN mitigates age-associated physiological decline in mice (Cell Metab 2016) — PubMed PMID: 28068222
  4. Yoshino, Baur, Imai — NAD+ intermediates NMN and NR (Cell Metab 2018) — PubMed PMID: 29249689
  5. Covarrubias et al. — NAD+ metabolism in cellular ageing (Nat Rev Mol Cell Biol 2021) — PubMed PMID: 33353981
  6. Kanfi et al. — SIRT6 overexpression extended lifespan in male mice (Nature 2012); a 2021 study (Roichman et al.) found longer life in both sexes — PubMed PMID: 22367546; PubMed PMID: 34050173
  7. SIRT3 and mitochondrial protection — PubMed: SIRT3 mitochondrial protection
  8. Camacho-Pereira — CD38 dictates age-related NAD decline and mitochondrial dysfunction (Cell Metab 2016) — PubMed PMID: 27304511
  9. FOXO transcription factor activation by sirtuins — PubMed: SIRT1-FOXO axis
  10. Caloric restriction mimicry via sirtuin activation — PubMed: caloric restriction mimicry
  11. Yang et al. (Sinclair laboratory) — Loss of epigenetic information as a cause of mammalian aging, a mouse study behind the Information Theory of Aging (Cell 2023) — PubMed PMID: 36638792
  12. Telomere maintenance and SIRT6 — PubMed: SIRT6 telomere maintenance

Back to Table of Contents

Research Papers: Cognition & Brain

  1. Tarantini et al. — NMN rescues cerebromicrovascular endothelial function in aged mice (Redox Biol 2019) — PubMed PMID: 31015147
  2. Igarashi et al. — NMN 250 mg a day in 42 randomized older men, 20 analysed at 12 weeks; cognition unchanged; funded by an NMN manufacturer (npj Aging 2022) — Search PubMed
  3. Orr et al. — NR in 20 older adults with mild cognitive impairment raised blood NAD+ but did not change cognition (GeroScience 2024) — PubMed PMID: 37994989
  4. Yao et al. — NMN in an Alzheimer's mouse model (amyloid-beta reduction) (Neurosci Lett 2017) — Search PubMed
  5. NMN neurovascular coupling and spatial memory — PubMed: NMN neurovascular coupling
  6. Grozio et al. — Slc12a8 reported as an NMN transporter in the mouse small intestine (Nat Metab 2019); disputed by Schmidt & Brenner (2019) — PubMed PMID: 31131364; PubMed PMID: 32694648
  7. Brakedal et al. — NADPARK, a phase I trial of NR in Parkinson's disease (Cell Metab 2022); Berven et al. — NR-SAFE, a high-dose safety trial (Nat Commun 2023) — PubMed PMID: 35235774; PubMed PMID: 38016950
  8. NAD+ and neuroinflammation — PubMed: NAD+ neuroinflammation
  9. NMN and traumatic brain injury — PubMed: NMN TBI
  10. NAD+ and the gut-brain axis — PubMed: NAD+ gut-brain axis

Back to Table of Contents

Research Papers: Energy & Mitochondria

  1. NAD+/NADH ratio and Complex I electron transport — PubMed: NAD+/NADH and Complex I
  2. Mitochondrial unfolded protein response (UPRmt) and NAD+ — PubMed: UPRmt and NAD+
  3. SIRT1-PGC1alpha and mitochondrial biogenesis — PubMed: SIRT1-PGC1α biogenesis
  4. AMPK and sirtuin cross-talk — PubMed: AMPK-SIRT1 cross-talk
  5. NMN supplementation and exercise capacity in amateur runners (Liao 2021) — PubMed PMID: 34238308
  6. NAD+ and chronic fatigue syndrome — PubMed: NAD+ chronic fatigue syndrome
  7. Grant et al. — 6-hour IV NAD+ infusion pilot in 11 healthy men aged 30 to 55 (Front Aging Neurosci 2019) — PubMed PMID: 31572171
  8. NAD+ in long-COVID and post-viral fatigue — PubMed: NAD+ long-COVID fatigue
  9. NMN insulin sensitivity in prediabetic women (Yoshino Science 2021) — PubMed PMID: 33888596
  10. Cardiac NAD+ and heart failure — PubMed: cardiac NAD+ and heart failure

Back to Table of Contents

Research Papers: NAD Precursors & Pharmacokinetics

  1. Martens et al. — Chronic NR is safe and elevates NAD+ in middle-aged adults (Nat Commun 2018) — PubMed PMID: 29599478
  2. Pencina et al. — a pharmaceutical-grade NMN tablet produced substantial dose-related increases in blood NAD+ in a 14-day trial in 32 overweight or obese adults aged 55 to 80 (J Gerontol A 2023) — PubMed PMID: 35182418
  3. Yi et al. — NMN safety and efficacy in healthy middle-aged adults (GeroScience 2023) — PubMed PMID: 36482258
  4. Brenner critique — methylation cofactor depletion and the NR vs NMN debate — PubMed: Brenner methylation critique
  5. Niacin (NA) vs niacinamide (NAM) vs NR vs NMN pharmacokinetics — PubMed: B3 precursor PK comparison
  6. Niacin vasodilator flush and GPR109A — PubMed: niacin flush mechanism
  7. Yaku et al. — most oral NMN and NR converted by gut bacteria to nicotinic acid in mice (Sci Adv 2025); Christen et al. — NR and NMN comparably raised blood NAD+ in a 2026 human comparison (Nat Metab 2026) — Search PubMed; Search PubMed
  8. FDA letters of 11 October and 4 November 2022 excluding NMN, and the FDA response of 29 September 2025 reversing the exclusion — regulations.gov FDA-2022-S-0023-0051; regulations.gov FDA-2023-P-0872-2754 (see FDA Reverses Course: NMN Allowed in Dietary Supplements)
  9. Sublingual vs oral NMN bioavailability — PubMed: sublingual vs oral NMN
  10. Khatri, Abdellatif & Sedej — Clinical evidence for the use of NAD+ precursors to slow aging (Geromedicine 2025; not indexed in PubMed) — doi:10.70401/geromedicine.2025.0008

Back to Table of Contents

Research Papers: Cross-Cutting (Safety, Regulation, Mechanism)

  1. McReynolds et al. — median tissue NAD+ decrease of about 30% in aged mice (Cell Syst 2021); Trętowicz et al. — whole-blood NAD+ stable with age in seven human cohorts (Nat Metab 2026) — PubMed PMID: 34559996; PubMed PMID: 42135539
  2. NAMPT (rate-limiting salvage enzyme) and circadian regulation — PubMed: NAMPT and circadian biology
  3. NAD+ and CLOCK-BMAL1 feedback loop (Nakahata, Ramsey Science 2009) — PubMed PMID: 19286518; PubMed PMID: 19299583
  4. NAD+ and female reproductive aging in mice (Bertoldo Cell Rep 2020; Miao Cell Rep 2020) — PubMed PMID: 32049001; PubMed PMID: 32755581
  5. NAD+ and skin aging — PubMed: NAD+ and skin aging
  6. Yang et al. — safety meta-analysis of randomized NMN trials (Nutrients 2026) — PubMed PMID: 42514320
  7. PARP1 NAD+ consumption under DNA damage stress — PubMed: PARP1 NAD+ consumption
  8. De novo NAD+ synthesis from tryptophan via kynurenine — PubMed: tryptophan-kynurenine NAD+ synthesis
  9. NAD+ precursors and cancer in preclinical studies: Nacarelli (Nat Cell Biol 2019), Maric (Biosens Bioelectron 2023), Nakazzi (Cancer Lett 2026) — Search PubMed; Search PubMed; PubMed PMID: 41724424
  10. Verdin — NAD+ in aging, metabolism, and neurodegeneration (Science 2015) — PubMed PMID: 26785480

Back to Table of Contents

External Authoritative Resources

Back to Table of Contents

Connections

Back to Table of Contents